Literature DB >> 11323216

Clinical significance of enzyme-linked immunosorbent assay for the detection of circulating anti-BP180 autoantibodies in patients with bullous pemphigoid.

Y Amo1, T Ohkawa, M Tatsuta, Y Hamada, T Fujimura, K Katsuoka, T Hashimoto.   

Abstract

The NC16A domain of the 180-kDa bullous pemphigoid antigen (BP180) is the most immunogenic and, probably, pathogenic region in bullous pemphigoid (BP). In the present study, in order to determine whether serum level of circulating anti-BP180 autoantibodies is a valuable serum marker in BP, the immunoreactivity of sera against the NC16A domain of BP180 was measured using enzyme-linked immunosorbent assay (ELISA) in ten patients with BP. Serum levels of anti-BP180 autoantibodies correlated with the clinical course in BP patients, who received various therapeutic agents. The result suggests that this NC16A-ELISA is a useful method for evaluating the clinical course and efficacy of the therapy in patients with BP.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11323216     DOI： 10.1016/s0923-1811(00)00149-3

Source DB:  PubMed          Journal:  J Dermatol Sci        ISSN： 0923-1811            Impact factor:   4.563


  14 in total

Review 1.  Unraveling the significance of IgE autoantibodies in organ-specific autoimmunity: lessons learned from bullous pemphigoid.

Authors:  K A N Messingham; H M Holahan; J A Fairley
Journal:  Immunol Res       Date:  2014-08       Impact factor: 2.829

2.  Eosinophil localization to the basement membrane zone is autoantibody- and complement-dependent in a human cryosection model of bullous pemphigoid.

Authors:  Kelly N Messingham; Jeffrey W Wang; Heather M Holahan; Rupasree Srikantha; Samantha C Aust; Janet A Fairley
Journal:  Exp Dermatol       Date:  2015-11-23       Impact factor: 3.960

Review 3.  Clinical and serological responses following plasmapheresis in bullous pemphigoid: two case reports and a review of the literature.

Authors:  Brian Chang; Ashok Tholpady; Richard S P Huang; Elena Nedelcu; Yu Bai
Journal:  Blood Transfus       Date:  2014-04       Impact factor: 3.443

4.  T cell participation in autoreactivity to NC16a epitopes in bullous pemphigoid.

Authors:  W J Pickford; V Gudi; A M Haggart; B J Lewis; R Herriot; R N Barker; A D Ormerod
Journal:  Clin Exp Immunol       Date:  2015-05       Impact factor: 4.330

5.  Evaluation of recombinant antigen-based assays for diagnosis of bullous autoimmune diseases.

Authors:  G D'Agosto; A Latini; M Carducci; A Mastroianni; A Vento; P Cordiali Fei
Journal:  Clin Diagn Lab Immunol       Date:  2004-07

6.  Diagnosis and clinical severity markers of bullous pemphigoid.

Authors:  Enno Schmidt; Detlef Zillikens
Journal:  F1000 Med Rep       Date:  2009-02-24

7.  A novel ELISA reveals high frequencies of BP180-specific IgE production in bullous pemphigoid.

Authors:  Kelly A N Messingham; Megan H Noe; Marisa A Chapman; George J Giudice; Janet A Fairley
Journal:  J Immunol Methods       Date:  2009-05-05       Impact factor: 2.303

8.  Missing the target: characterization of bullous pemphigoid patients who are negative using the BP180 enzyme-linked immunosorbant assay.

Authors:  Janet A Fairley; Matthew Bream; Colleen Fullenkamp; Sergei Syrbu; Mei Chen; Kelly N Messingham
Journal:  J Am Acad Dermatol       Date:  2012-10-18       Impact factor: 11.527

9.  Usefulness of Enzyme-linked Immunosorbent Assay Using Recombinant BP180 and BP230 for Serodiagnosis and Monitoring Disease Activity of Bullous Pemphigoid.

Authors:  Eui Hyung Lee; Yeon Hee Kim; Sinyoung Kim; Song-Ee Kim; Soo-Chan Kim
Journal:  Ann Dermatol       Date:  2012-02-02       Impact factor: 1.444

10.  Human eosinophils express the high affinity IgE receptor, FcεRI, in bullous pemphigoid.

Authors:  Kelly N Messingham; Heather M Holahan; Alexandra S Frydman; Colleen Fullenkamp; Rupasree Srikantha; Janet A Fairley
Journal:  PLoS One       Date:  2014-09-25       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.